Abstract: The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against inflammatory disease or conditions, and related embodiments; said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disease or condition, as well as their preparation; pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment, and related embodiments.

Abstract: The present invention primarily relates to the use of certain extract formulations of Rhodamnia cinerea as defined herein as alpha-amylase inhibitors and as actives for the therapeutic (including prophylactic) treatment of a carbohydrate metabolic disorder or of a disease attendant on hyperglycemia, preferably selected from the group consisting of prediabetes, obesity, hyperlipemia, arteriosclerosis, arteriolosclerosis, atherosclerosis, diabetes, postprandial hyperglycemia, and metabolic syndrome. The present invention also relates to corresponding methods. The invention further relates to specific extract formulations obtainable from Rhodamnia cinerea and to compositions, in particular orally consumable compositions, comprising an effective amount of such an extract formulation.

Abstract: The invention relates to cyclopentabenzofuran derivatives for the treatment and/or prophylaxis of angiogenesis-related disorders.

Abstract: The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with an estrogen receptor (ER) related disease or condition of the animal or human body, as well as methods, uses and other inventions related thereto.

Abstract: The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with a phosphodiesterase (PDE) dependent disease or condition of the central nervous system, as well as methods, uses and other inventions related thereto.

Abstract: The invention relates to the use of cycloventabenzofuran derivatives for the production of a medicament for the treatment of nuclear factor of &kgr;B-dependent diseases.

Abstract: A process for removing finishing agents containing silicone oil from textile substrates in an aqueous medium free of halogenated hydrocarbons, wherein the removing agent is a composition containing, as an essential ingredient, a surfactant carrying cationic groups on the surfactant framework structure, and which may also contain acids, non-ionic surfactants, water-soluble non-ionic polymers and solvents (free of halogenated hydrocarbons).

Abstract: The present invention relates to a method for textile printing with aqueous dispersions in which an organic fixing agent is crosslinked with a blocked polyisocyanate having (i) an average molecular weight of about 800 to about 25,000, (ii) a content of blocked isocyanate groups, calculated as free NCO and based on non-blocked polyisocyanate, corresponding to an NCO content of about 5 to about 20% by weight, (iii) an ionic group content of about 1 to about 75 milliequivalents per 100 g of blocked polyisocyanate, and (iv) a content of polyalkylene oxide units of about 1 to about 20% by weight, based on blocked polyisocyanate, said blocked polyisocyanate being obtained by the reaction of(a) organic polyisocyanates,(b) isocyanate-reactive compounds containing (potential) ionic groups,(c) polyalkylene ether alcohols,(d) NCO blocking agents, and(e) optionally, isocyanate-reactive compounds that are different from components (b), (c), and (d).